| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/30/2004 | CA2743313A1 Angiotensin-converting enzyme inhibitory peptides |
| 09/30/2004 | CA2526891A1 Angiotensin-converting enzyme inhibitory peptides |
| 09/30/2004 | CA2524255A1 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 09/30/2004 | CA2522786A1 Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| 09/30/2004 | CA2522380A1 Specific inhibition of allorejection |
| 09/30/2004 | CA2520629A1 Methods of promoting the differentiation of stem cells |
| 09/30/2004 | CA2519863A1 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 09/30/2004 | CA2519860A1 Short interfering rna (sirna) analogues |
| 09/30/2004 | CA2519457A1 Compounds and their use for specific and simultaneous inhibition of genes involved in diseases and related drugs |
| 09/30/2004 | CA2519414A1 Methods of treating inflammatory diseases associated with bone destruction |
| 09/30/2004 | CA2519412A1 Combined use of g-csf and factors having angiogenic action |
| 09/30/2004 | CA2519131A1 Ligands for tgf-beta binding proteins and uses thereof |
| 09/30/2004 | CA2519120A1 Methods of administering a material into a patient for dermal enhancement |
| 09/30/2004 | CA2519092A1 Branched water-soluble polymers and their conjugates |
| 09/30/2004 | CA2519027A1 Agent comprise an albumin-like first polypeptide bound to a second polypeptide |
| 09/30/2004 | CA2519023A1 Facially amphiphilic polymers and oligomers and uses thereof |
| 09/30/2004 | CA2519020A1 Method for the production of gla-residue containing serine proteases |
| 09/30/2004 | CA2518830A1 Carboxamide spirohydantoin cgrp receptor antagonists |
| 09/30/2004 | CA2518550A1 Cancer treatment using proanp peptides |
| 09/30/2004 | CA2518327A1 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
| 09/30/2004 | CA2518265A1 Novel cyclosporins |
| 09/30/2004 | CA2517588A1 Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
| 09/30/2004 | CA2517191A1 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy |
| 09/30/2004 | CA2516990A1 Treatment of alzheimer's disease |
| 09/30/2004 | CA2516726A1 Amylin aggregation inhibitors and use thereof |
| 09/29/2004 | EP1462518A1 Adipocyte differentiation-associated gene and protein |
| 09/29/2004 | EP1462457A1 Cytotoxic protein and utilization thereof |
| 09/29/2004 | EP1462455A1 Novel peptides and medicinal uses thereof |
| 09/29/2004 | EP1462114A1 Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18) |
| 09/29/2004 | EP1462113A1 CELL GROWTH INHIBITOR CONTAINING ANTI-PepT ANTIBODY |
| 09/29/2004 | EP1462112A1 Remedies for dry eye and diseases associated with dry eye |
| 09/29/2004 | EP1462111A1 Composition for inducing immunotolerance |
| 09/29/2004 | EP1462109A1 Hemostatic, emollient and lubricating preparations containing pork fat extract (lard) |
| 09/29/2004 | EP1462102A1 A method for promoting gonadal growth in an animal |
| 09/29/2004 | EP1462096A1 Methods and compositions for pulmonary delivery of insulin |
| 09/29/2004 | EP1461620A2 Flexible method and apparatus for high throughput production and purification of multiple proteins |
| 09/29/2004 | EP1461614A2 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
| 09/29/2004 | EP1461610A2 Heme-regulated eukaryotic initiation factor 2 alpha kinase knockout mice and methods for use |
| 09/29/2004 | EP1461463A2 Antisense modulation of hematopoietic cell protein tyrosine kinase expression |
| 09/29/2004 | EP1461461A2 Antisense modulation of cd81 expression |
| 09/29/2004 | EP1461450A1 T-bet compositions and methods of use thereof |
| 09/29/2004 | EP1461449A2 System for monitoring bacterial tumor treatment |
| 09/29/2004 | EP1461446A2 Lipid-associated molecules |
| 09/29/2004 | EP1461445A2 Glycoprotein remodeling using endoglycanases |
| 09/29/2004 | EP1461444A2 Glycopeptide remodeling using amidases |
| 09/29/2004 | EP1461443A2 Carbohydrate-associated proteins |
| 09/29/2004 | EP1461427A2 Methods for targeted expression of therapeutic nucleic acid |
| 09/29/2004 | EP1461421A2 A method for the establishment of a pluripotent human blastocyst-derived stem cell line |
| 09/29/2004 | EP1461419A2 Antisense modulation of phospholipid scramblase 3 expression |
| 09/29/2004 | EP1461360A2 Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours |
| 09/29/2004 | EP1461358A1 Ifnar2 muteins, their production and use |
| 09/29/2004 | EP1461357A2 Novel hev antigenic peptide and methods |
| 09/29/2004 | EP1461356A2 Hexa-, hepta-, and octapeptides having antiangiogenic activity |
| 09/29/2004 | EP1461352A2 Antisense modulation of connective tissue growth factor expression |
| 09/29/2004 | EP1461351A2 Methods and reagents for diagnosis and treatment of diabetes |
| 09/29/2004 | EP1461349A2 Antisense modulation of mhc class ii transactivator expression |
| 09/29/2004 | EP1461348A2 Antisense modulation of phospholipid scramblase 4 expression |
| 09/29/2004 | EP1461087A1 Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| 09/29/2004 | EP1461086A2 Enzymatic cleavable reagents for specific delivery to disease sites |
| 09/29/2004 | EP1461082A2 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
| 09/29/2004 | EP1461080A2 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
| 09/29/2004 | EP1461079A2 Human immunodeficiency virus envelope clycoprotein mutants and uses thereof |
| 09/29/2004 | EP1461076A2 Methods and compositions for treating lesions of the respiratory epithelium |
| 09/29/2004 | EP1461073A2 Peptide agonists of prostate-specific antigen, and uses therefor |
| 09/29/2004 | EP1461072A1 Proteases producing an altered immunological response and methods of making and using the same |
| 09/29/2004 | EP1461071A1 Muscle transcription factors |
| 09/29/2004 | EP1461070A2 Combined use of a glp-1 compound and a modulator of diabetic late complications |
| 09/29/2004 | EP1461069A2 Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| 09/29/2004 | EP1461068A1 Methods of compositions for normalizing lipid levels in mammalian tissues |
| 09/29/2004 | EP1461067A1 Compositions and method for treating hepatitis virus infection |
| 09/29/2004 | EP1461066A1 The use of il6r/il6 chimera in nerve cell regeneration |
| 09/29/2004 | EP1461065A1 Erythropoietin dosing regimen for treating anemia |
| 09/29/2004 | EP1461063A2 Treatment of glioblastoma with thymosin-alpha 1 |
| 09/29/2004 | EP1461062A2 Composition and method for treating chronic allograft rejection |
| 09/29/2004 | EP1461053A2 Storage-stable fibrin sealant |
| 09/29/2004 | EP1461049A1 Use of sulfated glycosaminoglycans for establishing effective labor in women |
| 09/29/2004 | EP1461033A2 Methods and compositions for ameliorating the undesirable effects of chemotherapy |
| 09/29/2004 | EP1461023A2 Prospective identification and characterization of breast cancer stem cells |
| 09/29/2004 | EP1461020A1 Synthesis of small particles |
| 09/29/2004 | EP1461014A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
| 09/29/2004 | EP1461001A2 Cancer-associated epitope |
| 09/29/2004 | EP1461000A2 Materials and methods for making improved micelle compositions |
| 09/29/2004 | EP1460992A2 Stabilized reverse micelle compositions and uses thereof |
| 09/29/2004 | EP1460900A2 Human secreted proteins |
| 09/29/2004 | EP1460898A1 Wt1 antisense oligos for the inhibition of breast cancer |
| 09/29/2004 | EP1385874A4 Alpha conotoxin peptides with analgesic properties |
| 09/29/2004 | EP1351941B1 Bisaryl derivatives having fsh receptor modulatory activity |
| 09/29/2004 | EP1276493B1 Cxcr4 agonist treatment of hematopoietic cells |
| 09/29/2004 | EP1244462B1 Pharmaceutical composition comprised of spider venoms, the production thereof, and its use for treating tumor diseases |
| 09/29/2004 | EP1169339B1 Macrocyclic peptides inhibiting the hepatitis c virus ns3 protease |
| 09/29/2004 | EP1147130A4 Alpha-conotoxin peptides |
| 09/29/2004 | EP1144412B1 Immunosuppressive effects of pteridine derivatives |
| 09/29/2004 | EP1140980B1 Pseudopeptide compounds having an inhibiting activity with respect to paths activated by proteins with active tyrosine kinase activity and pharmaceutical compositions containing same |
| 09/29/2004 | EP1090116B1 Transgenic non-human animal which comprises an inactive peg3 gene, and the use thereof |
| 09/29/2004 | EP1060185A4 Isolated nucleic acid molecules which encode tage molecules, and uses thereof |
| 09/29/2004 | EP1059913B1 Emulsion preconcentrates containing cyclosporin or a macrolide |
| 09/29/2004 | EP1042463B1 Target for treating atherosclerosis, obesity and type ii diabetes |
| 09/29/2004 | EP1030688B1 Method for dermally administering polypeptides |
| 09/29/2004 | EP1023078A4 Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma |
| 09/29/2004 | EP1015012A4 Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |